New drug combo tested for tough cancers
NCT ID NCT00600496
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researchers also studied how the drugs move through the body.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AZD6244 (also called ARRY-142886) combined with standard chemotherapies
- What this could lead to
- If successful, this could point toward a new combination treatment option for advanced solid tumors.
- What could go wrong
- This is a very early Phase 1 trial focused on safety, not effectiveness. The combination may cause side effects or not work against the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
140 people
The number who actually took part.
- Started
-
Dec 2007
- Finished
-
Dec 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 130 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients will have measurable and/or non-measurable disease, lacking curative options for whom the selected chemotherapy agents represent the standard of care * WHO performance status 0-1 * Patients must be able to swallow AZD6244 capsules Exclusion Criteria: * Prior treatment with a MEK inhibitor * Participation in a clinical study during the last 30 days or have not recovered from side effects of an investigational study drug * Brain metastases or spinal cord compression unless treated and stable (for at least 1 month) off steroids
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a personalized menu keep cancer patients stronger through chemotherapy?
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?